Literature DB >> 15384982

Tetramolecular immune complexes are more efficient than IVIg to prevent antibody-dependent in vitro and in vivo phagocytosis of blood cells.

Renée Bazin1, Réal Lemieux, Tony Tremblay, Isabelle St-Amour.   

Abstract

Intravenous immunoglobulins (IVIg) have immunomodulatory effects in vivo and are widely used in the treatment of autoimmune diseases, such as idiopathic thrombocytopenic purpura (ITP). The mechanisms by which IVIg can prevent platelet clearance in ITP patients are not fully understood but are known to require the participation of low affinity Fcgamma receptors (FcgammaRs), which interact poorly with monomeric immunoglobulin G (IgG). Given the importance of low affinity FcgammaRs in the treatment of ITP, we hypothesized that immune complexes (IC) produced in vitro could reproduce the effects of IVIg. Small-size tetramolecular IC were prepared using mouse monoclonal anti-human IgG and human Fc fragments. The effects of tetramolecular IC and IVIg on the in vitro and in vivo inhibition of phagocytosis of opsonized blood cells were compared. The results obtained showed that tetramolecular IC were at least six times more efficient than IVIg to prevent phagocytosis of opsonized red blood cells in vitro, and clearance of platelets in the thrombocytopenic mouse model. Copyright 2004 Blackwell Publishing Ltd

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15384982     DOI: 10.1111/j.1365-2141.2004.05105.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  13 in total

1.  Immune complexes as therapy for autoimmunity.

Authors:  Raphael Clynes
Journal:  J Clin Invest       Date:  2005-01       Impact factor: 14.808

2.  Variability of the inhibition by total immunoglobulin of in vitro autoantibody-mediated erythrophagocytosis by mouse macrophages.

Authors:  S Léonard; I Pierard; T E Michaelsen; S Izui; P L Masson; J-P Coutelier
Journal:  Clin Exp Immunol       Date:  2006-07       Impact factor: 4.330

3.  Highly parallel characterization of IgG Fc binding interactions.

Authors:  Austin W Boesch; Eric P Brown; Hao D Cheng; Maame Ofua Ofori; Erica Normandin; Peter A Nigrovic; Galit Alter; Margaret E Ackerman
Journal:  MAbs       Date:  2014 Jul-Aug       Impact factor: 5.857

4.  Neutralization of mitogenic lectins by intravenous immunoglobulin (IVIg) prevents T cell activation: does IVIg really have a direct effect on T cells?

Authors:  L Padet; I St-Amour; É Aubin; R Bazin
Journal:  Clin Exp Immunol       Date:  2011-12       Impact factor: 4.330

5.  A fully recombinant human IgG1 Fc multimer (GL-2045) inhibits complement-mediated cytotoxicity and induces iC3b.

Authors:  Hua Zhou; Henrik Olsen; Edward So; Emmanuel Mérigeon; Denis Rybin; Jane Owens; Gregory LaRosa; David S Block; Scott E Strome; Xiaoyu Zhang
Journal:  Blood Adv       Date:  2017-03-14

6.  Divergent intracellular sorting of Fc{gamma}RIIA and Fc{gamma}RIIB2.

Authors:  Christine Y Zhang; James W Booth
Journal:  J Biol Chem       Date:  2010-08-24       Impact factor: 5.157

7.  Recombinant IgG2a Fc (M045) multimers effectively suppress experimental autoimmune myasthenia gravis.

Authors:  Muthusamy Thiruppathi; Jian Rong Sheng; Liangcheng Li; Bellur S Prabhakar; Matthew N Meriggioli
Journal:  J Autoimmun       Date:  2014-01-02       Impact factor: 7.094

8.  Co-opting endogenous immunoglobulin for the regulation of inflammation and osteoclastogenesis in humans and mice.

Authors:  Lindsay M MacLellan; Jennifer Montgomery; Fujimi Sugiyama; Susan M Kitson; Katja Thümmler; Gregg J Silverman; Stephen A Beers; Robert J B Nibbs; Iain B McInnes; Carl S Goodyear
Journal:  Arthritis Rheum       Date:  2011-12

9.  Optimization of an enrichment process for circulating tumor cells from the blood of head and neck cancer patients through depletion of normal cells.

Authors:  Liying Yang; James C Lang; Priya Balasubramanian; Kris R Jatana; David Schuller; Amit Agrawal; Maciej Zborowski; Jeffrey J Chalmers
Journal:  Biotechnol Bioeng       Date:  2009-02-01       Impact factor: 4.530

10.  Fully recombinant IgG2a Fc multimers (stradomers) effectively treat collagen-induced arthritis and prevent idiopathic thrombocytopenic purpura in mice.

Authors:  Ajay Jain; Henrik S Olsen; Ravi Vyzasatya; Erin Burch; Yukimi Sakoda; Emmanuel Y Mérigeon; Ling Cai; Changwan Lu; Ming Tan; Koji Tamada; Dan Schulze; David S Block; Scott E Strome
Journal:  Arthritis Res Ther       Date:  2012-08-20       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.